肿瘤细胞治疗研究
FRONTIER PAPERS
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.
尽管在治疗多种血液系统恶性肿瘤方面取得了显著成功，但使用嵌合抗原受体（CAR）T细胞的细胞免疫疗法在治疗难治/复发性或髓系恶性肿瘤如AML、CML或多发性骨髓瘤时仍面临重大挑战。
A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.
中国（1,006 项试验）和美国（549 项试验）占所有研究的 80% 以上。
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane
将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。
Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.
嵌合抗原受体（CAR）T 细胞疗法彻底改变了淋巴瘤和多发性骨髓瘤等血液系统恶性肿瘤的治疗。
CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.
这些发现支持将 CXCR4 修饰作为提高 CAR-T 细胞治疗血液系统 B 细胞恶性肿瘤疗效的策略，值得进一步临床研究。
Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.
作为开创性的免疫治疗手段，CAR-T 细胞与NK 细胞（CAR-NK）疗法在治疗多种血液系统恶性肿瘤时已显示出显著的临床疗效。
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
CAR-T 细胞治疗彻底改变了血液系统恶性肿瘤的治疗，提供了一种高度个体化且强效的免疫治疗手段。
BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.
CAR-T 细胞疗法尚未在老年新诊断多发性骨髓瘤（NDMM）患者中常规开展研究，因此我们评估了 AZD0120 作为 70 岁 MM 患者一线治疗的效果。
Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.
共纳入 18 项研究，涵盖 1400 余例患者。
MEMBER ACCOUNT
登录成功会直接打开下一页。
